Chunk #34 — Discussion and concluding remarks — Clinical perspectives

Source

15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse.

Embedded

yes

Text

Further development of delta and kappa opioid drugs will join the growing body of studies addressing other targets, such as gamma-aminobutyric acid receptors and voltage-gated ion channels. These drugs will likely complete other non-pharmacological therapies, including transcranial magnetic stimulation or behavioral, cognitive therapies and group therapies considered very effective in long-term treatments (Addolorato et al., 2012; Volkow and Skolnick, 2012).